Table 1.
Reference | miRNA | Expression Level | Endpoint | Outcome | Independent in Multivariate Analysis |
---|---|---|---|---|---|
papillary RCC | |||||
Ge et al., 2015 [78] | miR-200c | ↓ | OS | good | no |
miR-127 | ↓ | OS | good | no | |
miR-34a | ↑ | OS | good | yes | |
Luo et al., 2017 [79] | hsa-miR-1293 | ↑ | PFS | poor | N/E |
hsa-miR-3199-2 | ↑ | PFS | poor | N/E | |
Huang et al., 2017 [80] | miR-133a | ↑ | OS | poor | N/E |
miR-133b | ↑ | OS | poor | N/E | |
miR-145 | ↑ | OS | poor | no | |
miR-216a | ↑ | OS | poor | N/E | |
miR-217 | ↑ | OS | poor | N/E | |
miR-1297 | ↑ | OS | poor | N/E | |
miR-211 | ↑ | OS | good | N/E | |
chromophobe RCC | |||||
Ge et al., 2015 [81] | miR-191 | ↑ | RFS, OS | poor | no |
miR-19a | ↑ | RFS, OS | poor | no | |
miR-210 | ↑ | RFS, OS | poor | yes (RFS) | |
miR-425 | ↑ | RFS, OS | poor | no | |
miR-186 | ↑ | OS | poor | no |
Abbreviations: RCC—renal cell carcinoma; OS—overall survival; PFS—progression-free survival; RFS—recurrence-free survival; N/E—not evaluated, no multivariate analysis conducted.